US › Healthcare

Allogene Therapeutics Inc (ALLO)

US · Healthcare · Biotechnology

$1.90+3.26%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-42.6M
Profit YoY
+28.7%
EPS
$-0.18
EPS estimate
$-0.18

EPS came in at -0.18 against a street estimate of -0.18 — a beat of 0.0%.

Key statistics

Market cap
$635.1M
Forward P/E
0.0
P/B
2.33
Book value
$1.14
EPS (TTM)
$-0.77
52-week high
$4.46
52-week low
$0.98
50-day MA
$1.97
200-day MA
$1.86
Beta
0.47

Analyst view

Analysts rate Allogene Therapeutics Inc a buy (12 buy, 2 hold, 0 sell out of 14) with an average price target of $9.00.

Shareholding

Insiders
11.04%
Institutions
55.06%

Largest institutional holders

FundStake
Pfizer Inc6.39%
BlackRock Inc5.53%
TPG GP A, LLC5.42%
State Street Corp2.51%
PRIMECAP Management Company2.43%
Vanguard Capital Management, LLC2.01%
Citadel Advisors Llc1.97%
T. Rowe Price Associates, Inc.1.56%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Allogene Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.